299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,695 / Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

6 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00924547 (ClinicalTrials.gov)	November 2013	17/6/2009	Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis	Oral Docosahexanoic Acid Supplementation in Cystic Fibrosis: Effects on Exhaled Pro-inflammatory Isoprostanes and Analysis of Its Esterification Sites in Plasma	Cystic Fibrosis	Dietary Supplement: Docosahexanoic Acid Supplement;Dietary Supplement: Placebo	Vanderbilt University	NULL	Completed	6 Years	N/A	Both	17	Phase 2	United States
2	NCT03045198 (ClinicalTrials.gov)	March 2012	2/2/2017	Effect of Azithromycin on Fatty Acids in CF	Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis	Cystic Fibrosis	Drug: Azithromycin	University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)	University of Bonn;University Hospital, Frankfurt	Unknown status	10 Years	60 Years	All	20	Phase 4	NULL
3	NCT01783613 (ClinicalTrials.gov)	October 2011	31/1/2013	Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis	Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid administration: 50 mg/kg/day during 12 months;Dietary Supplement: Placebo: 50 mg/kg/day during 12 months	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal	NULL	Completed	2 Months	100 Years	All	96	N/A	Spain
4	EUCTR2010-020516-11-IT (EUCTR)	16/09/2010	28/09/2010	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND	CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY MedDRA version: 9.1;Level: PT;Classification code 10033628 MedDRA version: 9.1;Classification code 10011762	Trade Name: PREFOLIC30CPR GASTROR 15MG INN or Proposed INN: Detoxifying agents for antineoplastic treatment Trade Name: INDUSILOS GTT FL 30MG+FL 15ML INN or Proposed INN: Cobamamide	AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Italy
5	NCT02690857 (ClinicalTrials.gov)	May 2010	16/2/2016	Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)	Efficacy of Docosahexanoic Acid on Lipid Peroxidation in Subjects With Cystic Fibrosis	Cystic Fibrosis	Drug: Docosahexaenoic acid;Drug: Sunflower Oil	Hospices Civils de Lyon	NULL	Completed	6 Years	30 Years	Male	10	Phase 2	NULL
6	NCT00530244 (ClinicalTrials.gov)	March 2003	13/9/2007	Use of Formula Fortified With DHA in Infants With Cystic Fibrosis	The Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)	Cystic Fibrosis	Dietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)	University of Massachusetts, Worcester	Cystic Fibrosis Foundation	Completed	N/A	56 Days	All	76	N/A	United States